Skip to content

Roche Holding AG

🇨🇭XSWX.ROSwitzerlandNot reported

CHF 375.20CHFdown -1.20 (-0.32%)ClosedEnd of day9:54 AM

PriceCHF 375.20-1.20 (-0.32%)

Latest anomalies

Neutral 7 detected in the last 120 days

  • High: 2
  • Medium: 2
  • Low: 3
  • 52-week high: the price is trading close to this level

    Price Low

  • Volume: a spike above the 20-day average

    Price High

  • Daily return: an extreme move up, far outside its trailing 60-day range

    Price Medium

  • Volume: a spike above the 20-day average

    Price High

  • 52-week high: the price is trading close to this level

    Price Low

View all anomalies

Free with a Finzer account.

Profile

  • Switzerland

Identity

Type
Stock
ISIN
CH0012032113
CUSIP
Not reported

Company

Employees
Not reported
Headquarters
Germany
Website
Not reported

Market

Shares outstanding
106.7M
Market cap
CHF 40.03B

Highlights

Day rangeCHF 372.00 - CHF 377.80
today's session
52-week rangeCHF 264.60 - CHF 383.00
from 249 sessions
Market cap
CHF 40.03B
EPS LTM
CHF 13.81
P/E LTM
27.17calculatedCalculated by Finzer, not reported by the data provider.
Div yield
6.3%calculatedCalculated by Finzer, not reported by the data provider.

Fundamentals (LTM)

Revenue
CHF 60.77B-5.62%down year on year
Net income
CHF 11.03B-24.76%down year on year
Gross margin
72.64%+5.89%up year on year
Free cash flow
CHF 11.69B-32.8%down year on year

View all financials

Latest news

News is not sourced for this exchange.

Business summary

Roche Holding AG is listed on SIX Swiss Exchange (Switzerland) under the ticker RO. Its market capitalisation is CHF 40.03B, from 106.7M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHF 264.60 and CHF 383.00, and the last close of CHF 375.20 sits 93% of the way up that range. The same company also trades as ROG on Cboe Canada - NEO-L (Market by Order), and as RHO on Frankfurt Stock Exchange.

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.